Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832884 | 0.85 | PRKDC (0.44) | ERN1TDP1PRKDCLMNAALDH1A1 | |
| SCHEMBL1808858 | 0.82 | TDP1 (0.48) | ERN1TDP1LMNAALDH1A1 | |
| SCHEMBL633623 | 0.82 | ERN1 (0.45) | ERN1TDP1PRKDCLMNAKDM1A | |
| SCHEMBL1965867 | 0.82 | TDP1 (0.43) | ERN1TDP1LMNAALDH1A1 | |
| SCHEMBL31618920 | 0.80 | TDP1 (0.41) | ERN1TDP1LMNAALDH1A1KDM1A | |
| SCHEMBL1972414 | 0.80 | TDP1 (0.41) | ERN1TDP1LMNAALDH1A1KDM1A | |
| SCHEMBL3366443 | 0.78 | PRKDC (0.45) | ERN1TDP1PRKDCLMNAALDH1A1 | |
| SCHEMBL604322 | 0.78 | TDP1 (0.43) | ERN1TDP1LMNAALDH1A1KDM1A | |
| SCHEMBL22164044 | 0.77 | TDP1 (0.43) | ERN1TDP1PRKDCLMNAALDH1A1 | |
| SCHEMBL248719 | 0.76 | ERN1 (0.50) | ERN1TDP1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211119-B1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4240363-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3551635-B1 | THIENO-INDENO-MONOMERS AND POLYMERS | BASF SE (DE) | 2021-04-28 | — | — | EP | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| CN-110582502-A | Thieno-indeno-monomers and polymers | 巴斯夫欧洲公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3551635-A2 | THIENO-INDENO-MONOMERS AND POLYMERS | BASF SE (DE) | 2019-10-16 | — | — | EP | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018104367-A2 | THIENO-INDENO-MONOMERS AND POLYMERS | BASF SE (DE) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018104367-A2 | THIENO-INDENO-MONOMERS AND POLYMERS | BASF SE (DE) | 2018-06-14 | — | — | WO | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | ERN1 1402/4885TDP1 1272/4885AHR 2183/4885 |
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, CLK2 | ERN1 1149/4885TDP1 1271/4885AHR 2424/4885 |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | ERN1 1013/4885TDP1 4476/4885AHR 2073/4885 |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, PDXK, HIPK1 | ERN1 1237/4885TDP1 842/4885AHR 2420/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | ERN1 1013/4885TDP1 4476/4885AHR 2073/4885 |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | ERN1 1176/4885TDP1 899/4885AHR 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.